Aptevo Therapeutics (APVO) Enterprise Value (2016 - 2025)
Aptevo Therapeutics (APVO) has disclosed Enterprise Value for 11 consecutive years, with -$3.2 million as the latest value for Q3 2025.
- Quarterly Enterprise Value rose 58.38% to -$3.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$3.2 million through Sep 2025, up 58.38% year-over-year, with the annual reading at -$7.5 million for FY2024, 101.79% down from the prior year.
- Enterprise Value hit -$3.2 million in Q3 2025 for Aptevo Therapeutics, up from -$8.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.6 million in Q3 2023 to a low of -$62.9 million in Q2 2021.
- Historically, Enterprise Value has averaged -$22.8 million across 5 years, with a median of -$21.0 million in 2023.
- Biggest five-year swings in Enterprise Value: plummeted 564.96% in 2021 and later skyrocketed 92.89% in 2023.
- Year by year, Enterprise Value stood at -$45.0 million in 2021, then skyrocketed by 49.75% to -$22.6 million in 2022, then skyrocketed by 83.51% to -$3.7 million in 2023, then tumbled by 101.79% to -$7.5 million in 2024, then skyrocketed by 57.16% to -$3.2 million in 2025.
- Business Quant data shows Enterprise Value for APVO at -$3.2 million in Q3 2025, -$8.1 million in Q2 2025, and -$2.1 million in Q1 2025.